[{"address1": "The Omeros Building", "address2": "201 Elliott Avenue West", "city": "Seattle", "state": "WA", "zip": "98119", "country": "United States", "phone": "206 676 5000", "website": "https://www.omeros.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.", "fullTimeEmployees": 198, "auditRisk": 8, "boardRisk": 8, "compensationRisk": 10, "shareHolderRightsRisk": 5, "overallRisk": 9, "governanceEpochDate": 1717200000, "maxAge": 86400, "priceHint": 4, "previousClose": 3.955, "open": 3.99, "dayLow": 3.9, "dayHigh": 4.06, "regularMarketPreviousClose": 3.955, "regularMarketOpen": 3.99, "regularMarketDayLow": 3.9, "regularMarketDayHigh": 4.06, "beta": 1.357, "forwardPE": -2.0050504, "volume": 538576, "regularMarketVolume": 538576, "averageVolume": 360553, "averageVolume10days": 444680, "averageDailyVolume10Day": 444680, "bid": 3.91, "ask": 4.01, "bidSize": 100, "askSize": 100, "marketCap": 230038480, "fiftyTwoWeekLow": 0.92, "fiftyTwoWeekHigh": 5.84, "fiftyDayAverage": 3.5774, "twoHundredDayAverage": 3.1307, "currency": "USD", "enterpriseValue": 471852320, "floatShares": 55398093, "sharesOutstanding": 57944200, "sharesShort": 13541632, "sharesShortPriorMonth": 13132553, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.2337, "heldPercentInsiders": 0.04394, "heldPercentInstitutions": 0.44145, "shortRatio": 52.41, "shortPercentOfFloat": 0.24440001, "impliedSharesOutstanding": 57944200, "bookValue": -1.231, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -179087008, "trailingEps": -2.91, "forwardEps": -1.98, "pegRatio": -0.02, "enterpriseToEbitda": -2.827, "52WeekChange": -0.2648148, "SandP52WeekChange": 0.26238096, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "OMER", "underlyingSymbol": "OMER", "shortName": "Omeros Corporation", "longName": "Omeros Corporation", "firstTradeDateEpochUtc": 1255008600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "3f7c487e-99e5-35b0-97bc-8da48930057f", "messageBoardId": "finmb_32388", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.97, "targetHighPrice": 43.0, "targetLowPrice": 43.0, "targetMeanPrice": 43.0, "targetMedianPrice": 43.0, "recommendationMean": 2.3, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 230334000, "totalCashPerShare": 3.975, "ebitda": -166912992, "totalDebt": 472148000, "quickRatio": 4.03, "currentRatio": 4.757, "returnOnAssets": -0.21031, "freeCashflow": -119943624, "operatingCashflow": -141592992, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]